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Background
Mammalian fed-batch processes for monoclonal anti-
body (mAb) production rely on strategic feeding of sev-
eral nutrients such as glucose, vitamins and amino acids
to extend culture time and improve protein production
[1]. In actual processes, L-cysteine and L-tyrosine are
fed separately at alkaline pH due their low stability and
low solubility at neutral pH, resulting in pH peaks and
precipitations [2]. To simplify next generation processes,
both amino acids have been chemically modified to
enhance their respective stability and solubility profiles.
Previous work has demonstrated that phosphotyrosine
disodium salt (PTyr2Na) is a stable L-tyrosine derivative
and can be used in neutral pH feeds without having a
detectable impact on the culture performance or the
mAb quality attributes [3]. Here, we present results
obtained using a L-cysteine derivative in a neutral pH,
single-feed system.
Materials and methods
The stability of the L-cysteine derivative was evaluated
in neutral pH, CellventoTM Feed-220 during three
months at room temperature or 4°C.For fed-batch cul-
tures, a CHO K1 clone expressing a human mAb was
used. Cultivation was performed in the Cellvento™
CHO-220 media system according to the product pro-
cess guidance. For controls, Cellvento™ Feed-220 and a
separate alkaline cysteine/tyrosine feed were used
whereas in the single feed process, the L-cysteine deriva-
tive and PTyr2Na were directly solubilized in the neutral
pH, main feed. Experiments were performed in spin
tubes and 1.2L bioreactors. Growth and viability were
monitored using a ViCell®,titer was determined using
Cedex Bio HT and specific productivity was calculated
based on titer, integral viable cell density and dilution.
For spent media analysis, the L-cysteine derivative and
amino acid quantification was performed by UPLCusing
AccQ·TagTMUltra Reagent. To assess the reactive
potential of the feed, H2DCFDA was added to the neu-
tral pH, Cellvento™ Feed-220 supplemented or not with
the derivative. For intracellular reactive species quantifi-
cation, cells were labeled with carboxy-H2DCFDA and
fluorescence was measured. To evaluate the capacity of
the cells to metabolize the derivative, cell lysates were
spiked and formed products were quantified by UPLC.
For mAb analysis, N-glycosylation was quantified using
HPLC after 2-AB labeling, whereas charge variants were
determined using cIEF.
Results
Analysis of the L-cysteine derivative stability in neutral
pH feed indicated no change in the derivative concen-
tration nor L-cysteine/L-cystine release when stored
over three months at room temperature or 4°C. No pre-
cipitation or color change was observed indicating that
the derivative was stable under the tested conditions.
Fed-batch cultivation in spin tubes with the single-feed
strategy resulted in higher final viabilities leading to
enhanced final titers when compared to the control con-
dition. Spin tube results were confirmed in bioreactors
leading to higher final viabilities, increased titers and
higher specific productivity with the single feed strategy.
Lower dye oxidation was measured after addition of
H2DCFDA to neutral pH, Cellvento™ Feed-220 con-
taining the derivative compared to feed alone indicating
lower reactive potential. Lower intracellular dye oxida-
tion was detected by addition of carboxy-H2DCFDA to
spin tube single-feed fed-batch cultures indicating lower
intracellular reactive species generation when using the
derivative. When spiked into cell lysates, the cysteine
derivative was metabolized to cysteine. No difference in
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produced mAb indicating no influence of the derivative
on the presented critical quality attributes.
Conclusions
This study demonstrates that the L-cysteine derivative
and PTyr2Na can be integrated into a neutral pH feed
and can be used as a source of L-cysteine in fed-batch
processes leading to a higher specific productivity com-
pared to the state-of-the-art process without affecting
mAb critical quality attributes.
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